PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG)

Authors
Category Primary study
JournalNeuro-Oncology
Year 2023
This article has no abstract
Epistemonikos ID: f21ef00995767dce22e599a7b9a8a5149a296790
First added on: Feb 17, 2025